vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是弗雷斯特研究公司的1.5倍（$156.4M vs $101.1M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs -6.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 0.5%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
BCRX vs FORR — 直观对比
营收规模更大
BCRX
是对方的1.5倍
$101.1M
营收增速更快
BCRX
高出13.9%
-6.5%
两年增速更快
BCRX
近两年复合增速
0.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $101.1M |
| 净利润 | — | $-33.9M |
| 毛利率 | — | 56.7% |
| 营业利润率 | 13.6% | -36.6% |
| 净利率 | — | -33.5% |
| 营收同比 | 7.5% | -6.5% |
| 净利润同比 | — | -7941.4% |
| 每股收益（稀释后） | $0.00 | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXFORR
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $101.1M | ||
| Q3 25 | $159.4M | $94.3M | ||
| Q2 25 | $163.4M | $111.7M | ||
| Q1 25 | $145.5M | $89.9M | ||
| Q4 24 | $131.5M | $108.0M | ||
| Q3 24 | $117.1M | $102.5M | ||
| Q2 24 | $109.3M | $121.8M |
净利润BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $-33.9M | ||
| Q3 25 | $12.9M | $-2.1M | ||
| Q2 25 | $5.1M | $3.9M | ||
| Q1 25 | $32.0K | $-87.3M | ||
| Q4 24 | $-26.8M | $432.0K | ||
| Q3 24 | $-14.0M | $-5.8M | ||
| Q2 24 | $-12.7M | $6.3M |
毛利率BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 56.7% | ||
| Q3 25 | 98.6% | 60.0% | ||
| Q2 25 | 98.3% | 55.5% | ||
| Q1 25 | 96.9% | 55.9% | ||
| Q4 24 | 95.4% | 58.8% | ||
| Q3 24 | 97.3% | 60.5% | ||
| Q2 24 | 98.4% | 57.3% |
营业利润率BCRXFORR
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | -36.6% | ||
| Q3 25 | 18.6% | 4.7% | ||
| Q2 25 | 18.2% | 6.2% | ||
| Q1 25 | 14.6% | -97.5% | ||
| Q4 24 | -3.4% | -0.5% | ||
| Q3 24 | 6.6% | -0.7% | ||
| Q2 24 | 8.0% | 9.3% |
净利率BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | -33.5% | ||
| Q3 25 | 8.1% | -2.3% | ||
| Q2 25 | 3.1% | 3.5% | ||
| Q1 25 | 0.0% | -97.1% | ||
| Q4 24 | -20.4% | 0.4% | ||
| Q3 24 | -12.0% | -5.7% | ||
| Q2 24 | -11.6% | 5.2% |
每股收益（稀释后）BCRXFORR
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $-1.75 | ||
| Q3 25 | $0.06 | $-0.11 | ||
| Q2 25 | $0.02 | $0.20 | ||
| Q1 25 | $0.00 | $-4.62 | ||
| Q4 24 | $-0.13 | $0.02 | ||
| Q3 24 | $-0.07 | $-0.30 | ||
| Q2 24 | $-0.06 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $63.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $126.5M |
| 总资产 | $465.1M | $404.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXFORR
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $63.3M | ||
| Q3 25 | $212.9M | $65.1M | ||
| Q2 25 | $260.0M | $67.8M | ||
| Q1 25 | $295.1M | $75.6M | ||
| Q4 24 | $320.9M | $56.1M | ||
| Q3 24 | $96.8M | $62.8M | ||
| Q2 24 | $78.4M | $58.9M |
股东权益BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $126.5M | ||
| Q3 25 | $-387.9M | $157.7M | ||
| Q2 25 | $-421.6M | $159.5M | ||
| Q1 25 | $-451.9M | $147.4M | ||
| Q4 24 | $-475.9M | $229.5M | ||
| Q3 24 | $-468.6M | $234.3M | ||
| Q2 24 | $-475.6M | $237.1M |
总资产BCRXFORR
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $404.0M | ||
| Q3 25 | $446.4M | $414.2M | ||
| Q2 25 | $457.2M | $436.0M | ||
| Q1 25 | $480.0M | $439.8M | ||
| Q4 24 | $490.4M | $503.9M | ||
| Q3 24 | $491.3M | $505.3M | ||
| Q2 24 | $472.4M | $524.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-4.3M |
| 自由现金流率自由现金流/营收 | — | -4.2% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $18.1M |
8季度趋势，按日历期对齐
经营现金流BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $-3.2M | ||
| Q3 25 | $41.6M | $1.2M | ||
| Q2 25 | $41.3M | $-3.6M | ||
| Q1 25 | $-27.5M | $26.7M | ||
| Q4 24 | $-5.2M | $-1.8M | ||
| Q3 24 | $8.2M | $264.0K | ||
| Q2 24 | $-1.4M | $-2.9M |
自由现金流BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $-4.3M | ||
| Q3 25 | $40.3M | $524.0K | ||
| Q2 25 | $41.1M | $-4.2M | ||
| Q1 25 | $-27.7M | $26.1M | ||
| Q4 24 | $-5.9M | $-2.5M | ||
| Q3 24 | $8.2M | $-223.0K | ||
| Q2 24 | $-1.5M | $-3.7M |
自由现金流率BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | -4.2% | ||
| Q3 25 | 25.3% | 0.6% | ||
| Q2 25 | 25.2% | -3.8% | ||
| Q1 25 | -19.0% | 29.0% | ||
| Q4 24 | -4.5% | -2.3% | ||
| Q3 24 | 7.0% | -0.2% | ||
| Q2 24 | -1.4% | -3.1% |
资本支出强度BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 1.1% | ||
| Q3 25 | 0.8% | 0.7% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.1% | 0.7% | ||
| Q4 24 | 0.5% | 0.6% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.1% | 0.7% |
现金转化率BCRXFORR
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | -0.93× | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
